Table 2. Experimental layout of PmSLP cattle trials.

Trial	Location	Animal	Treatment Groups	Schedule/ Route/Date of Blood Collection
1	Saskatoon, Canada	2–4 month old beef cattle (mixed breeds representative of beef cattle utilized in Canada) N = 9 per group	Vaccine: 200 μg BRD-PmSLP* + 20% (v/v) Montanide Gel02 + 30 μg Poly (I:C) in 2 mL Control: 20% (v/v) Montanide Gel 02 + 30 μg Poly (I:C) in 2 mL	3 doses (Day 0, 21, 42) Intramuscular Bleeds (Day 0, 21, 42, 63)
2	Debre Zeyit, Ethiopia	4–6 month old Zebu cattle N = 12–14 per group***	Vaccine: 200 μg BRD-PmSLP** + 20% (v/v) Montanide Gel 02 + 30 μg Poly (I:C) in 2 mL Controls: 20% (v/v) Montanide Gel 02 + 30 μg Poly (I:C) in 2 mL 1% ALK(SO4)2.12H2O in 2 mL	3 doses, (Day 0, 21, 42) Subcutaneous Bleeds (Day 0, 21, 35, 60)
3	Calgary, Canada	4–6 month old Holstein cattle N = 5 per group	Vaccines: 200 μg HS-PmSLP* + 20% (v/v) Montanide Gel 02 + 30 μg Poly (I:C) in 2 mL 200 μg HS-PmSLP + 0.148% Alhydrogel in 2 mL	2 doses (Day 0, 21) Subcutaneous Bleeds (Day 0, 21, 56)
4	Debre Zeyit, Ethiopia	1–2 year old Zebu cattle N = 8 per group	Vaccines: 200 μg HS-PmSLP** + 20% (v/v) Montanide Gel 02 + 30 μg Poly (I:C) in 2 mL 200 μg HS-PmSLP + 0.148% Alhydrogel in 2 mL Control: 20% (v/v) Montanide Gel 02 in 2 mL	2 doses (Day 0, 21) Subcutaneous Bleeds (Day 0, 21, 35)

*antigen shipped on dry ice and stored at -80°C until vaccine preparation

**lyophilized antigen shipped at ambient temperature to Ethiopia and stored at 4°C until vaccine preparation

***in the vaccinated group, all 12 animals received doses 1 and 2, but only 6 animals received a third dose of vaccine. In the control group, 10 animals received doses 1 and 2 of Montanide Gel 02 + 30 μg Poly (I:C), but 6 animals received a third dose of adjuvant only. An additional 4 animals in the control group received two doses of aluminum potassium sulfate adjuvant.